Todd Chappell, MBA has experience running multiple drug development programs from discovery stage through to clinical trials. He also has experience working as an EIR at NIH and spent some time working in biotech venture capital, running a portfolio company that was acquired by Tetralogic Pharmaceuticals after bringing a lead compound to clinical trials.
|
Suresh Singh, PhD established the computational design group at Vitae Pharmaceuticals, which was acquired by Allergan, using SILCS technology. At Vitae he launched 7 drug development programs, 6 of which went to clinical trials. Most recently he served as Vice President of Computational Sciences at Hotspot Therapeutics, which recently raised a $45M series A financing.
|
W. Alex Meltzer, PhD is an expert in drug target identification and validation as a cancer and stem cell biologist. Prior to Rasio Therapeutics, Dr. Meltzer was a senior associate at a life science/deep tech start-up firm where he brought several life science products to market and a portfolio company to revenue. He also has experience as a biotech equity research analyst fellow at T. Rowe Price and a life science venture fellow at Osage University Partners
|
Ken Malone, PhD has been CEO of SilcsBio for seven years and led the formation of Rasio. As a serial entrepreneur, he provides strategic guidance and governance to Rasio.
|
Advisors
Curt Civin, MD is a pioneer in cancer research who is known internationally for developing a way to isolate stem cells from other blood cells . The founding director for the University of Maryland’s Center for Stem Cell Biology & Regenerative Medicine. Dr. Civin is the co-inventor and lead scientist of the ART derivatives program.
Sujuan Ba, PhD serves as President and CEO of the National Foundation for Cancer Research (NFCR). She is the founding President and CEO of the AIM-HI Translational Research Fund, and the Founder and CEO of the Asian Fund for Cancer Research. In addition, Dr. Ba co-founded and serves as a founding board member of the Global Coalition for Adaptive Research (GCAR).
Michael Wang, MD, PHD, MBA has extensive experience in scientific program management, strong capability for technical and financial due diligence, and broad knowledge about early-stage technology evaluation and development. Dr. Wang has previously served as Chief Science Officer overseeing all the aspects of the NFCR’s cancer research programs and research initiatives.
Sujuan Ba, PhD serves as President and CEO of the National Foundation for Cancer Research (NFCR). She is the founding President and CEO of the AIM-HI Translational Research Fund, and the Founder and CEO of the Asian Fund for Cancer Research. In addition, Dr. Ba co-founded and serves as a founding board member of the Global Coalition for Adaptive Research (GCAR).
Michael Wang, MD, PHD, MBA has extensive experience in scientific program management, strong capability for technical and financial due diligence, and broad knowledge about early-stage technology evaluation and development. Dr. Wang has previously served as Chief Science Officer overseeing all the aspects of the NFCR’s cancer research programs and research initiatives.
|
National Science Foundation |
© 2019 Rasio All Rights Reserved
